retatrutide triple agonist obesity π¨ HOT OFF THE PRESS: Phase 3 data has arrived β and the medicine world is paying attention. In Lilly's TRIUMPH-1 trial, participants receiving the highest dose achieved an average triple-hormone-receptor agonist retatrutide for obesity
Pay in 4 interest-free payments of $7.03 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 1 - Aug 6





















![Mox Emerald [Beta Edition] Commander](https://cdn.shopify.com/s/files/1/0266/3209/3801/products/87cc8726-0483-5dfa-8ee2-ce3bd9657ebe.jpg?v=1681706898)




![Lich [Beta Edition] San Diego Comic-Con 2014](https://cdn.shopify.com/s/files/1/0266/3209/3801/products/fad51126-6b44-5199-b6ed-1221677fe92e.jpg?v=1681706688)